Survey participants have gut health misconceptions
CINCINNATI A recent GfK Roper "Gut Check" survey, sponsored by the Align brand, revealed that approximately 1-in-4 survey participants experience occasional digestive upsets, and of those, 1-in-5 have been told that these disruptive upsets are caused by their attitude or emotions, Procter & Gamble announced Wednesday.
"I see the frustration occasional digestive upsets cause my patients," stated Roshini Rajapaksa, a gastroenterologist at NYU Langone Medical Center. "The first step to building a stronger inside is to better understand how your digestive system works and what you can do to keep it healthy,” she said. "To help improve both their health and lifestyle, I teach my patients that it comes down to simple science — it is important to have the right balance of good and bad bacteria in the gut. When we replenish the good bacteria with probiotics it helps maintain a healthy digestive system."
Although probiotics, or good bacteria that provide a health benefit, have been in use for more than 100 years, the survey also found that people still have misconceptions about their gut health:
- 43% of those surveyed believed that most types of bacteria are not helpful for the GI tract;
- More than 40% believed that all probiotics essentially have the same benefits and are not strain specific; and
- A large majority (77%) thought that probiotics found in supplements are not as natural as those found in foods.
The "Gut Check" survey findings also showed that digestive upsets can interrupt daily life. Of those who experienced occasional digestive upsets, more than half felt their upsets impacted their self confidence. Eight-in-10 tried to go about their day normally, but most still made adjustments to their activities. Nearly half missed an event or trip or avoided a social situation because of an occasional digestive upset, and more than one-third of survey respondents changed their diet to deal with their digestive upsets.
Proantinox may reduce UTI incidence in women, study suggests
EDISON, N.J. A recent study being published in the journal Urology found that Proantinox, a proprietary cranberry-based blend found in DSE Healthcare Solutions’ Cystex liquid cranberry complex with Proantinox, is safe and effective in significantly reducing the incidence of urinary tract infections in women at risk for recurring infections.
The study, conducted by Aaron Katz, professor of clinical urology at Columbia University college of physicians and surgeons, also found that those women who took the recommended doses of the formula significantly improved quality of life as measured by the American Urological Association Symptom Index.
“The objectives of this study initially were to determine the safety, tolerability and maximum dose necessary of the proprietary Proantinox formula, but the secondary finding of efficacy was so significant, we felt it was worth noting,” stated Katz. “Normally you would expect at least 32% to 36% of the participants, based on history, to have at least one more infection or UTI symptoms during the study period, but we found only 9% of the sample had this occur.”
The study looked at 28 women, ages 18 to 75 years, who had experienced at least two or more urinary tract infections in the past six months. In addition to the tolerability and efficacy findings, questionnaires were also completed at baseline, week four and week 12 to measure overall health and quality of life based on the AUA Symptom Index.
Perrigo gains OTC rights for generic Allegra products
ALLEGAN, Mich. Perrigo on Tuesday announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of fexofenadine HCl 180 mg and 60 mg tabs, plus fexofenadine HCl 60 mg and pseudoephedrine 120 mg tabs, the generic versions of Sanofi-Aventis’ Allegra and Allegra D-12 products, respectively.
Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of symptoms associated with seasonal allergies. Sanofi-Aventis has applied to the Food and Drug Administration for the Rx-to-OTC switch of these drugs, even going so far as to acquire OTC supplier Chattem as an in-house distribution arm for the allergy medicine.
It is assumed Allegra will be approved for its switch OTC, especially as an FDA advisory committee in 2001 recommended Allegra be eligible for switch.
Prior to generic competition entering the fexofenadine Rx market in 2005, Allegra 180 mg and 60 mg had combined annual sales of approximately $1.5 billion, and in 2009, Allegra D-12 had annual sales of $600 million according to data provided by Wolters-Kluwer.